Silvan Tuerkcan
Stock Analyst at Citizens
(4.12)
# 467
Out of 5,122 analysts
184
Total ratings
47.22%
Success rate
14.88%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $52.00 | +65.38% | 17 | Dec 23, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Market Outperform | $35 → $57 | $38.52 | +47.98% | 15 | Dec 11, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $8 → $10 | $5.90 | +69.49% | 5 | Nov 20, 2025 | |
| ENGN enGene Holdings | Maintains: Market Outperform | $18 → $21 | $9.97 | +110.63% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $13.05 | +60.92% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $4.72 | +69.49% | 14 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $12.59 | +74.74% | 14 | Nov 4, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $1.44 | +316.67% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $12.78 | +166.04% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $34.23 | +31.46% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $50 | $42.59 | +17.40% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $6.54 | +129.36% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $3.81 | +57.48% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $5.69 | +58.17% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $12.82 | +836.04% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.76 | +865.91% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $5.70 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $2.47 | +61.94% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $8.67 | +142.21% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.75 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.53 | +69.97% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $101.71 | +175.29% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $11.81 | +52.41% | 1 | Jan 26, 2023 |
CRISPR Therapeutics AG
Dec 23, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $52.00
Upside: +65.38%
Terns Pharmaceuticals
Dec 11, 2025
Maintains: Market Outperform
Price Target: $35 → $57
Current: $38.52
Upside: +47.98%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8 → $10
Current: $5.90
Upside: +69.49%
enGene Holdings
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $9.97
Upside: +110.63%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $13.05
Upside: +60.92%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $4.72
Upside: +69.49%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $12.59
Upside: +74.74%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $1.44
Upside: +316.67%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $12.78
Upside: +166.04%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $34.23
Upside: +31.46%
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $42.59
Upside: +17.40%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $6.54
Upside: +129.36%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $3.81
Upside: +57.48%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $5.69
Upside: +58.17%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $12.82
Upside: +836.04%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.76
Upside: +865.91%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $5.70
Upside: -
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $2.47
Upside: +61.94%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $8.67
Upside: +142.21%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.75
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $3.53
Upside: +69.97%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $101.71
Upside: +175.29%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $11.81
Upside: +52.41%